A biomarker substudy of the Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events—Thrombolysis in Myocardial Infarction 50 (TRA 2°P-TIMI 50) trial involving 15,833 patients with stable atherothrombotic disease reported a gradual association between elevated baseline concentrations of hs-cTnI and BNP and risk of HF hospitalization [27]. The gene discussed is F2R; the disease is hydrops fetalis.